Refuge Biotechnologies
Main focus: CAR-T cells for cancer treatment
Company stage: Clinical
Diseases: Breast cancer, head and neck cancer, liver cancer, diffuse large B-cell lymphoma (DLBCL)
Genome editing tool: CRISPR-Cas9/dCas9
Funding stage: Private
Location: Menlo Park, CA, USA
Website: https://refugebiotech.com/
Pipeline: https://refugebiotech.com/#programs
Partnerships: 3SBio
Refuge Biotech is a pre-clinical stage cancer immunotherapy company. The company uses a modified dCas9-based platform to engineer its CAR-T cell therapies, mainly for the treatment of solid tumours. Its dCas9 system is used in two ways: CRISPRa (activation) and CRISPRi (interference), which lead to either transcriptional activators or repression of target genes.